Deterministic sensitivity analyses were conducted for all parameters to evaluate the extent to which uncertainty and variability influenced model results. We studied ranges that corresponded to the reported 95% CI or interquartile range around a parameter and used whichever was largest. The base case of our model was calibrated to the STAMPEDE-H clinical trial in which patients received leuprolide acetate as standard of care. Given that therapies such as abiraterone are now being used for mHSPC based on the Long-Acting Therapy to Improve Treatment Success in Daily Life (LATITUDE) and STAMPEDE-G studies,6,7 we performed an additional analysis of the addition of abiraterone in the upfront setting to ADT and PRT. In addition, probabilistic sensitivity analyses using 10 000 Monte Carlo simulations while sampling with replacement from distributions of all input parameter inputs were performed to explore uncertainty with regard to the transition probabilities, costs, and utilities.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.